461030.KQ
IMBdx
KOE · Healthcare · Biotechnology · KR
KRW 2,960.00
+0.00%Year over year
Reported trailing growth
- Revenue
- +46.1%
- EBITDA
- -10.5%
- EBIT
- +17.9%
- EPS
- +5.2%
- Free cash flow
- -27.2%
- Operating cash flow
- -26.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +26.6%
- EBITDA
- +9.0%
- EBIT
- +18.4%
- Net income
- +17.2%
- EPS
- +17.2%
- Free cash flow
- +6.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026